{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T22:16:45Z","timestamp":1791670605463,"version":"4.3.4"},"reference-count":145,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"vor","delay-in-days":1461,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["kidney-international.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney International"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1016\/j.kint.2019.11.027","type":"journal-article","created":{"date-parts":[[2019,12,24]],"date-time":"2019-12-24T13:59:15Z","timestamp":1577195955000},"page":"664-675","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":51,"title":["Role of direct oral anticoagulants in patients with\u00a0kidney disease"],"prefix":"10.1016","volume":"97","author":[{"given":"Vimal K.","family":"Derebail","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle N.","family":"Rheault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1756-8271","authenticated-orcid":false,"given":"Bryce A.","family":"Kerlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.kint.2019.11.027_bib1","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.semnephrol.2018.08.004","article-title":"Risk stratification and treatment of coronary disease in chronic kidney disease and end-stage kidney disease","volume":"38","author":"Shroff","year":"2018","journal-title":"Semin Nephrol"},{"key":"10.1016\/j.kint.2019.11.027_bib2","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1111\/jth.12652","article-title":"Kidney disease and risk of venous thromboembolism: a nationwide population-based case-control study","volume":"12","author":"Christiansen","year":"2014","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.kint.2019.11.027_bib3","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1007\/s00467-014-3008-z","article-title":"Healthcare burden of venous thromboembolism in childhood chronic renal diseases","volume":"30","author":"Kerlin","year":"2015","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.kint.2019.11.027_bib4","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.blre.2011.07.001","article-title":"Bleeding and thrombotic complications of kidney disease","volume":"25","author":"Pavord","year":"2011","journal-title":"Blood Rev"},{"key":"10.1016\/j.kint.2019.11.027_bib5","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1097\/CRD.0000000000000044","article-title":"Pathophysiologic and treatment strategies for cardiovascular disease in end-stage renal disease and kidney transplantations","volume":"23","author":"Ghanta","year":"2015","journal-title":"Cardiol Rev"},{"key":"10.1016\/j.kint.2019.11.027_bib6","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/nrcardio.2013.15","article-title":"Management of cardiovascular disease in patients with kidney disease","volume":"10","author":"Kahn","year":"2013","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.kint.2019.11.027_bib7","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/j.kint.2016.09.049","article-title":"Diagnosis and management of atherosclerotic cardiovascular disease in chronic kidney disease: a review","volume":"91","author":"Mathew","year":"2017","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2019.11.027_bib8","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1097\/MNH.0000000000000280","article-title":"Cardiovascular complications in chronic dialysis patients","volume":"25","author":"Mavrakanas","year":"2016","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"10.1016\/j.kint.2019.11.027_bib9","doi-asserted-by":"crossref","first-page":"299","DOI":"10.5551\/jat.10454","article-title":"Chronic kidney disease, dyslipidemia, and atherosclerosis","volume":"19","author":"Shoji","year":"2012","journal-title":"J\u00a0Atheroscler Thromb"},{"key":"10.1016\/j.kint.2019.11.027_bib10","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1111\/tri.12413","article-title":"Cardiovascular morbidity and mortality after kidney transplantation","volume":"28","author":"Stoumpos","year":"2015","journal-title":"Transpl Int"},{"key":"10.1016\/j.kint.2019.11.027_bib11","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJMoa1709118","article-title":"Rivaroxaban with or without aspirin in stable cardiovascular disease","volume":"377","author":"Eikelboom","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2019.11.027_bib12","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa1112277","article-title":"Rivaroxaban in patients with a recent acute coronary syndrome","volume":"366","author":"Mega","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2019.11.027_bib13","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1007\/s11239-017-1483-3","article-title":"Oral antiplatelet drugs in patients with chronic kidney disease (CKD): a review","volume":"43","author":"Ibrahim","year":"2017","journal-title":"J\u00a0Thromb Thrombolysis"},{"key":"10.1016\/j.kint.2019.11.027_bib14","doi-asserted-by":"crossref","first-page":"665","DOI":"10.2215\/CJN.06790712","article-title":"Antiplatelet therapy in the management of cardiovascular disease in patients with CKD: what is the evidence?","volume":"8","author":"Jain","year":"2013","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2019.11.027_bib15","first-page":"373","article-title":"Antiplatelet agents in hemodialysis","volume":"30","author":"Migliori","year":"2017","journal-title":"J\u00a0Nephrol"},{"key":"10.1016\/j.kint.2019.11.027_bib16","first-page":"CD008834","article-title":"Antiplatelet agents for chronic kidney disease","volume":"2","author":"Palmer","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.kint.2019.11.027_bib17","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1097\/01.mnh.0000444820.80249.56","article-title":"Intersection of cardiovascular disease and kidney disease: atrial fibrillation","volume":"23","author":"Bansal","year":"2014","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"10.1016\/j.kint.2019.11.027_bib18","doi-asserted-by":"crossref","first-page":"2946","DOI":"10.1161\/CIRCULATIONAHA.111.020982","article-title":"Chronic kidney disease is associated with the incidence of atrial fibrillation: the Atherosclerosis Risk in Communities (ARIC) study","volume":"123","author":"Alonso","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.kint.2019.11.027_bib19","doi-asserted-by":"crossref","first-page":"173","DOI":"10.2215\/CJN.03170509","article-title":"Prevalence of atrial fibrillation and its predictors in nondialysis patients with chronic kidney disease","volume":"5","author":"Ananthapanyasut","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2019.11.027_bib20","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1161\/CIRCEP.110.957100","article-title":"Association of chronic kidney disease with atrial fibrillation among adults in the United States: REasons for Geographic and Racial Differences in Stroke (REGARDS) study","volume":"4","author":"Baber","year":"2011","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"10.1016\/j.kint.2019.11.027_bib21","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1097\/HJH.0b013e32833a7dfe","article-title":"Chronic kidney disease as an independent risk factor for new-onset atrial fibrillation in hypertensive patients","volume":"28","author":"Horio","year":"2010","journal-title":"J\u00a0Hypertens"},{"key":"10.1016\/j.kint.2019.11.027_bib22","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1016\/j.ahj.2010.03.027","article-title":"Chronic kidney disease and prevalent atrial fibrillation: the Chronic Renal Insufficiency Cohort (CRIC)","volume":"159","author":"Soliman","year":"2010","journal-title":"Am Heart J"},{"key":"10.1016\/j.kint.2019.11.027_bib23","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1038\/ki.2011.416","article-title":"The prevalence of and factors associated with chronic atrial fibrillation in Medicare\/Medicaid-eligible dialysis patients","volume":"81","author":"Wetmore","year":"2012","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2019.11.027_bib24","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1681\/ASN.2010050459","article-title":"The increasing prevalence of atrial fibrillation among hemodialysis patients","volume":"22","author":"Winkelmayer","year":"2011","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2019.11.027_bib25","doi-asserted-by":"crossref","first-page":"e812","DOI":"10.1542\/peds.2012-0267","article-title":"Trends in venous thromboembolism-related hospitalizations, 1994-2009","volume":"130","author":"Boulet","year":"2012","journal-title":"Pediatrics"},{"key":"10.1016\/j.kint.2019.11.027_bib26","doi-asserted-by":"crossref","first-page":"489S","DOI":"10.1378\/chest.114.5_Supplement.489S","article-title":"Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety","volume":"114","author":"Hirsh","year":"1998","journal-title":"Chest"},{"key":"10.1016\/j.kint.2019.11.027_bib27","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1177\/1060028017721241","article-title":"Quality of pharmacist-managed anticoagulation therapy in long-term ambulatory settings: a systematic review","volume":"51","author":"Manzoor","year":"2017","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.kint.2019.11.027_bib28","first-page":"523","article-title":"Effect of chronic kidney\u00a0disease on warfarin management in a pharmacist-managed\u00a0anticoagulation clinic","volume":"17","author":"Kleinow","year":"2011","journal-title":"J\u00a0Manag Care Pharm"},{"issue":"suppl 1","key":"10.1016\/j.kint.2019.11.027_bib29","first-page":"S68","article-title":"Current and future management of pediatric venous thromboembolism","volume":"87","author":"Kerlin","year":"2012","journal-title":"Am J Hematol"},{"key":"10.1016\/j.kint.2019.11.027_bib30","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1023\/A:1015368126304","article-title":"Argatroban","volume":"13","author":"Kathiresan","year":"2002","journal-title":"J\u00a0Thromb Thrombolysis"},{"key":"10.1016\/j.kint.2019.11.027_bib31","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1160\/TH07-10-0644","article-title":"Bivalirudin","volume":"99","author":"Warkentin","year":"2008","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.kint.2019.11.027_bib32","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1586\/erc.11.131","article-title":"Desirudin: a review of the pharmacology and clinical application for the prevention of deep vein thrombosis","volume":"9","author":"Graetz","year":"2011","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"10.1016\/j.kint.2019.11.027_bib33","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1111\/jth.12969","article-title":"Recommendation on the nomenclature for oral anticoagulants: communication from the SSC of the ISTH","volume":"13","author":"Barnes","year":"2015","journal-title":"J\u00a0Thromb Haemost"},{"issue":"5","key":"10.1016\/j.kint.2019.11.027_bib34","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCOUTCOMES.116.003476","volume":"10","author":"Katz","year":"2017","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"10.1016\/j.kint.2019.11.027_bib35","doi-asserted-by":"crossref","first-page":"k2505","DOI":"10.1136\/bmj.k2505","article-title":"Risks and benefits of direct oral anticoagulants versus warfarin in a real world setting: cohort study in primary care","volume":"362","author":"Vinogradova","year":"2018","journal-title":"BMJ"},{"key":"10.1016\/j.kint.2019.11.027_bib36","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1124\/dmd.113.054353","article-title":"Identification of carboxylesterase-dependent dabigatran etexilate hydrolysis","volume":"42","author":"Laizure","year":"2014","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.kint.2019.11.027_bib37","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1124\/dmd.107.019083","article-title":"The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans","volume":"36","author":"Blech","year":"2008","journal-title":"Drug Metab Dispos"},{"issue":"suppl E","key":"10.1016\/j.kint.2019.11.027_bib38","doi-asserted-by":"crossref","first-page":"E12","DOI":"10.1093\/eurheartj\/suy016","article-title":"Pharmacological properties of betrixaban","volume":"20","author":"Huisman","year":"2018","journal-title":"Eur Heart J Suppl"},{"key":"10.1016\/j.kint.2019.11.027_bib39","article-title":"Andexanet\u00a0alfa effectively reverses edoxaban anticoagulation effects and associated bleeding in a rabbit acute hemorrhage model","volume":"13","author":"Lu","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.kint.2019.11.027_bib40","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.tcm.2019.03.004","article-title":"A review of reversal of oral anticoagulants, old and new, in major bleeding and the need for urgent surgery","volume":"30","author":"Milling","year":"2020","journal-title":"Trends Cardiovasc Med"},{"key":"10.1016\/j.kint.2019.11.027_bib41","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1161\/CIRCRESAHA.112.276741","article-title":"Oral direct factor Xa inhibitors","volume":"111","author":"Yeh","year":"2012","journal-title":"Circ Res"},{"key":"10.1016\/j.kint.2019.11.027_bib42","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1056\/NEJMoa1707278","article-title":"Idarucizumab for dabigatran reversal\u2014full cohort analysis","volume":"377","author":"Pollack","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2019.11.027_bib43","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1056\/NEJMoa1607887","article-title":"Andexanet\u00a0alfa for acute major bleeding associated with factor Xa inhibitors","volume":"375","author":"Connolly","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2019.11.027_bib44","doi-asserted-by":"crossref","first-page":"107405","DOI":"10.1016\/j.pharmthera.2019.107405","article-title":"Antidotes for reversal of direct oral anticoagulants","volume":"204","author":"Dobesh","year":"2019","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.kint.2019.11.027_bib45","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1111\/bjh.15564","article-title":"The use of direct oral anticoagulants in chronic kidney disease","volume":"183","author":"Parker","year":"2018","journal-title":"Br J Haematol"},{"key":"10.1016\/j.kint.2019.11.027_bib46","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1016\/S0140-6736(54)92265-5","article-title":"The nephrotic syndrome associated with thrombosis of the renal veins","volume":"267","author":"Blainey","year":"1954","journal-title":"Lancet"},{"key":"10.1016\/j.kint.2019.11.027_bib47","doi-asserted-by":"crossref","first-page":"513","DOI":"10.2215\/CJN.10131011","article-title":"Epidemiology and pathophysiology of nephrotic syndrome-associated thromboembolic disease","volume":"7","author":"Kerlin","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2019.11.027_bib48","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1056\/NEJMcibr1209459","article-title":"Venous thrombosis in the nephrotic syndrome","volume":"368","author":"Loscalzo","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2019.11.027_bib49","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.jpeds.2009.01.070","article-title":"Epidemiology and risk factors for thromboembolic complications of childhood nephrotic syndrome: a Midwest Pediatric Nephrology Consortium (MWPNC) study","volume":"155","author":"Kerlin","year":"2009","journal-title":"J\u00a0Pediatr"},{"key":"10.1016\/j.kint.2019.11.027_bib50","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1038\/ki.2011.312","article-title":"Disease-specific risk of venous thromboembolic events is increased in idiopathic glomerulonephritis","volume":"81","author":"Barbour","year":"2012","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2019.11.027_bib51","doi-asserted-by":"crossref","first-page":"43","DOI":"10.2215\/CJN.04250511","article-title":"Venous thromboembolism in patients with membranous nephropathy","volume":"7","author":"Lionaki","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2019.11.027_bib52","first-page":"139","article-title":"KDIGO Clinical Practice Guideline for Glomerulonephritis","volume":"2","year":"2012","journal-title":"Kidney Int Suppl"},{"key":"10.1016\/j.kint.2019.11.027_bib53","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1038\/ki.2013.476","article-title":"Personalized prophylactic anticoagulation decision analysis in patients with membranous nephropathy","volume":"85","author":"Lee","year":"2014","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2019.11.027_bib54","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1159\/000188355","article-title":"Prevention of thrombotic complications of the nephrotic syndrome by the low-molecular-weight heparin enoxaparin","volume":"69","author":"Rostoker","year":"1995","journal-title":"Nephron"},{"key":"10.1016\/j.kint.2019.11.027_bib55","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1186\/s12882-019-1336-8","article-title":"Prophylactic anticoagulation in nephrotic syndrome prevents thromboembolic complications","volume":"20","author":"Kelddal","year":"2019","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.kint.2019.11.027_bib56","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/j.ekir.2018.02.010","article-title":"Direct-acting oral anticoagulants as prophylaxis against thromboembolism in the nephrotic syndrome","volume":"3","author":"Sexton","year":"2018","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.kint.2019.11.027_bib57","first-page":"739","article-title":"Rivaroxaban for the treatment of venous thromboembolism in patients with nephrotic syndrome and low AT-III: a pilot study","volume":"15","author":"Zhang","year":"2018","journal-title":"Exp Ther Med"},{"key":"10.1016\/j.kint.2019.11.027_bib58","first-page":"669","article-title":"Recurrent venous thromboembolism in primary membranous nephropathy despite direct Xa inhibitor therapy","volume":"32","author":"Reynolds","year":"2019","journal-title":"J\u00a0Nephrol"},{"key":"10.1016\/j.kint.2019.11.027_bib59","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1161\/ATVBAHA.109.189290","article-title":"Is diabetes mellitus an independent risk factor for venous thromboembolism? A population-based case-control study","volume":"29","author":"Heit","year":"2009","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.kint.2019.11.027_bib60","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.diabres.2017.11.024","article-title":"Does type 2 diabetes affect the on-treatment levels of direct oral anticoagulants in patients with atrial fibrillation?","volume":"135","author":"Samos","year":"2018","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.kint.2019.11.027_bib61","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1093\/ehjcvp\/pvu024","article-title":"Clinical outcomes of patients with diabetes and atrial fibrillation treated with apixaban: results from the ARISTOTLE trial","volume":"1","author":"Ezekowitz","year":"2015","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"10.1016\/j.kint.2019.11.027_bib62","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1161\/CIRCULATIONAHA.107.716951","article-title":"High absolute risks and predictors of venous and arterial thromboembolic events in patients with nephrotic syndrome: results from a large retrospective cohort study","volume":"117","author":"Mahmoodi","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.kint.2019.11.027_bib63","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1136\/annrheumdis-2019-215213","article-title":"EULAR recommendations for the management of antiphospholipid syndrome in adults","volume":"78","author":"Tektonidou","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.kint.2019.11.027_bib64","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/j.1538-7836.2006.01753.x","article-title":"International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)","volume":"4","author":"Miyakis","year":"2006","journal-title":"J\u00a0Thromb Haemost"},{"issue":"suppl 1","key":"10.1016\/j.kint.2019.11.027_bib65","doi-asserted-by":"crossref","first-page":"S43","DOI":"10.1016\/S0049-3848(17)30066-X","article-title":"Antiphospholipid syndrome","volume":"151","author":"Cervera","year":"2017","journal-title":"Thromb Res"},{"key":"10.1016\/j.kint.2019.11.027_bib66","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1182\/asheducation-2013.1.675","article-title":"Antiphospholipid syndrome","volume":"2013","author":"Lim","year":"2013","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.kint.2019.11.027_bib67","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1177\/0961203310395803","article-title":"Evidence-based recommendations for the prevention and long-term management of thrombosis in antiphospholipid antibody-positive patients: report of a task force at the 13th International Congress on antiphospholipid antibodies","volume":"20","author":"Ruiz-Irastorza","year":"2011","journal-title":"Lupus"},{"key":"10.1016\/j.kint.2019.11.027_bib68","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1093\/ndt\/17.10.1771","article-title":"Factors affecting outcome and prognosis in membranous lupus nephropathy","volume":"17","author":"Mercadal","year":"2002","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kint.2019.11.027_bib69","doi-asserted-by":"crossref","first-page":"e426","DOI":"10.1016\/S2352-3026(16)30079-5","article-title":"Rivaroxaban versus warfarin to treat patients with thrombotic antiphospholipid syndrome, with or without systemic lupus erythematosus (RAPS): a randomised, controlled, open-label, phase 2\/3, non-inferiority trial","volume":"3","author":"Cohen","year":"2016","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.kint.2019.11.027_bib70","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1093\/rheumatology\/kex086","article-title":"Failure of rivaroxaban to prevent thrombosis in four patients with anti-phospholipid syndrome","volume":"56","author":"Dufrost","year":"2017","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.kint.2019.11.027_bib71","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1007\/s10067-015-3030-y","article-title":"Thrombotic events in patients with antiphospholipid syndrome treated with rivaroxaban: a series of eight cases","volume":"35","author":"Signorelli","year":"2016","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.kint.2019.11.027_bib72","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1007\/s11926-016-0623-7","article-title":"Direct oral anticoagulants use in antiphospholipid syndrome: are these drugs an effective and safe alternative to warfarin? A systematic review of the literature","volume":"18","author":"Dufrost","year":"2016","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.kint.2019.11.027_bib73","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1182\/blood-2018-04-848333","article-title":"Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome","volume":"132","author":"Pengo","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.kint.2019.11.027_bib74","doi-asserted-by":"crossref","first-page":"685","DOI":"10.7326\/M19-0291","article-title":"Rivaroxaban versus vitamin K antagonist in antiphospholipid syndrome: a randomized noninferiority trial","volume":"171","author":"Ordi-Ros","year":"2019","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.kint.2019.11.027_bib75","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1160\/th14-03-0272","article-title":"Failure of dabigatran and rivaroxaban to prevent thromboembolism in antiphospholipid syndrome: a case series of three patients","volume":"112","author":"Schaefer","year":"2014","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.kint.2019.11.027_bib76","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1080\/03009742.2017.1369156","article-title":"Treatment failure of direct oral anticoagulants in anti-phospholipid syndrome","volume":"47","author":"Johnsen","year":"2018","journal-title":"Scand J Rheumatol"},{"key":"10.1016\/j.kint.2019.11.027_bib77","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1177\/1076029615615960","article-title":"Apixaban for the Secondary Prevention of Thrombosis Among Patients With Antiphospholipid Syndrome: study rationale and design (ASTRO-APS)","volume":"22","author":"Woller","year":"2016","journal-title":"Clin Appl Thromb Hemost"},{"key":"10.1016\/j.kint.2019.11.027_bib78","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1097\/MOH.0000000000000523","article-title":"Antiphospholipid syndrome in pediatric patients","volume":"26","author":"Tarango","year":"2019","journal-title":"Curr Opin Hematol"},{"key":"10.1016\/j.kint.2019.11.027_bib79","doi-asserted-by":"crossref","first-page":"e737S","DOI":"10.1378\/chest.11-2308","article-title":"Antithrombotic therapy in neonates and children: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines","volume":"141","author":"Monagle","year":"2012","journal-title":"Chest"},{"key":"10.1016\/j.kint.2019.11.027_bib80","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1002\/art.41017","article-title":"Association of pulmonary hemorrhage, positive proteinase 3, and urinary red blood cell casts\u00a0with\u00a0venous thromboembolism in antineutrophil cytoplasmic antibody-associated vasculitis","volume":"71","author":"Kronbichler","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.kint.2019.11.027_bib81","doi-asserted-by":"crossref","first-page":"620","DOI":"10.7326\/0003-4819-142-8-200505030-00011","article-title":"Brief communication: high incidence of venous thrombotic events among patients with Wegener granulomatosis: the Wegener\u2019s Clinical Occurrence of Thrombosis (WeCLOT) Study","volume":"142","author":"Merkel","year":"2005","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.kint.2019.11.027_bib82","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1002\/acr.22423","article-title":"High risk of pulmonary embolism and deep venous thrombosis but not of stroke in granulomatosis with polyangiitis (Wegener\u2019s)","volume":"66","author":"Faurschou","year":"2014","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.kint.2019.11.027_bib83","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.mayocp.2018.02.010","article-title":"Risk of cardiovascular disease and venous thromboembolism among patients with incident ANCA-associated vasculitis: a 20-year population-based cohort study","volume":"93","author":"Berti","year":"2018","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.kint.2019.11.027_bib84","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1002\/art.21704","article-title":"Thromboembolic events as a complication of antineutrophil cytoplasmic antibody-associated vasculitis","volume":"55","author":"Weidner","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.kint.2019.11.027_bib85","first-page":"704","article-title":"Clinical associations with venous thromboembolism in anti-neutrophil cytoplasm antibody-associated vasculitides","volume":"56","author":"Kronbichler","year":"2017","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.kint.2019.11.027_bib86","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1136\/ard.2008.099051","article-title":"High frequency of venous thromboembolic events in Churg-Strauss syndrome, Wegener\u2019s granulomatosis and microscopic polyangiitis but not polyarteritis nodosa: a systematic retrospective study on 1130 patients","volume":"68","author":"Allenbach","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.kint.2019.11.027_bib87","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s12969-015-0015-y","article-title":"Concurrent pulmonary hemorrhage and deep vein thrombosis in a child with ANCA-associated vasculitis: case\u00a0report and review of literature","volume":"13","author":"Tseng","year":"2015","journal-title":"Pediatr Rheumatol Online J"},{"key":"10.1016\/j.kint.2019.11.027_bib88","doi-asserted-by":"crossref","first-page":"2421","DOI":"10.1681\/ASN.2008030270","article-title":"Antibodies with dual reactivity to plasminogen and complementary PR3 in PR3-ANCA vasculitis","volume":"19","author":"Bautz","year":"2008","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2019.11.027_bib89","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1681\/ASN.2010030274","article-title":"Anti-plasminogen antibodies compromise fibrinolysis and associate with renal histology in ANCA-associated vasculitis","volume":"21","author":"Berden","year":"2010","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2019.11.027_bib90","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1681\/ASN.2011030298","article-title":"Anti-neutrophil cytoplasmic antibodies stimulate release of neutrophil microparticles","volume":"23","author":"Hong","year":"2012","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2019.11.027_bib91","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1136\/annrheumdis-2013-203430","article-title":"Tissue factor expression in neutrophil extracellular traps and neutrophil derived microparticles in antineutrophil cytoplasmic antibody associated vasculitis may promote thromboinflammation and the thrombophilic state associated with the disease","volume":"73","author":"Kambas","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.kint.2019.11.027_bib92","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1002\/art.39239","article-title":"Promotion of hypercoagulability in antineutrophil cytoplasmic antibody-associated vasculitis by C5a-induced tissue factor-expressing microparticles and neutrophil extracellular traps","volume":"67","author":"Huang","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.kint.2019.11.027_bib93","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1016\/j.ekir.2019.07.006","article-title":"Elevated microparticle tissue factor activity differentiates patients with venous thromboembolism in anti-neutrophil cytoplasmic autoantibody vasculitis","volume":"4","author":"Mendoza","year":"2019","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.kint.2019.11.027_bib94","doi-asserted-by":"crossref","first-page":"7","DOI":"10.23822\/EurAnnACI.1764-1489.80","article-title":"Hypersensitivity reactions to non-vitamin K oral anticoagulants\u2014a review of literature and diagnostic work-up proposal","volume":"51","author":"Carli","year":"2019","journal-title":"Eur Ann Allergy Clin Immunol"},{"key":"10.1016\/j.kint.2019.11.027_bib95","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.3899\/jrheum.130200","article-title":"Patients with antineutrophil cytoplasmic antibodies associated vasculitis in remission are hypercoagulable","volume":"40","author":"Hilhorst","year":"2013","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.kint.2019.11.027_bib96","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1016\/j.jacc.2014.09.051","article-title":"Net clinical benefit of antithrombotic therapy in patients with atrial fibrillation and chronic kidney disease: a nationwide observational cohort study","volume":"64","author":"Bonde","year":"2014","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.kint.2019.11.027_bib97","doi-asserted-by":"crossref","first-page":"3719","DOI":"10.1093\/ndt\/gfs346","article-title":"Should patients with advanced chronic kidney disease and atrial fibrillation receive chronic anticoagulation?","volume":"27","author":"Clase","year":"2012","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kint.2019.11.027_bib98","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1056\/NEJMoa1105594","article-title":"Stroke and bleeding in atrial fibrillation with chronic kidney disease","volume":"367","author":"Olesen","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2019.11.027_bib99","doi-asserted-by":"crossref","first-page":"2472","DOI":"10.1161\/STROKEAHA.117.017114","article-title":"Warfarin use in patients with atrial fibrillation undergoing hemodialysis: a nationwide population-based study","volume":"48","author":"Yoon","year":"2017","journal-title":"Stroke"},{"key":"10.1016\/j.kint.2019.11.027_bib100","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1681\/ASN.2009030319","article-title":"Warfarin use associates with increased risk for stroke in hemodialysis patients with atrial fibrillation","volume":"20","author":"Chan","year":"2009","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2019.11.027_bib101","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1161\/CIRCULATIONAHA.113.004777","article-title":"Warfarin use and the risk for stroke and bleeding in patients with atrial fibrillation undergoing dialysis","volume":"129","author":"Shah","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.kint.2019.11.027_bib102","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.kint.2018.05.005","article-title":"Chronic kidney disease and arrhythmias: highlights from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference","volume":"94","author":"Wanner","year":"2018","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2019.11.027_bib103","doi-asserted-by":"crossref","first-page":"181","DOI":"10.7326\/M19-0087","article-title":"Benefits and harms of oral anticoagulant therapy in chronic kidney disease: a systematic review and meta-analysis","volume":"171","author":"Ha","year":"2019","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.kint.2019.11.027_bib104","doi-asserted-by":"crossref","first-page":"2888","DOI":"10.1016\/j.jacc.2016.02.082","article-title":"Nonvitamin K anticoagulant agents in patients with advanced chronic kidney disease or on dialysis with AF","volume":"67","author":"Chan","year":"2016","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.kint.2019.11.027_bib105","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.ahj.2019.03.013","article-title":"Predictors of NOAC versus VKA use for stroke prevention in patients with newly diagnosed atrial fibrillation: results from GARFIELD-AF","volume":"213","author":"Haas","year":"2019","journal-title":"Am Heart J"},{"key":"10.1016\/j.kint.2019.11.027_bib106","first-page":"CD011373","article-title":"Direct oral anticoagulants versus warfarin for preventing stroke and systemic embolic events among atrial fibrillation patients with chronic kidney disease","volume":"11","author":"Kimachi","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.kint.2019.11.027_bib107","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.2215\/CJN.13811217","article-title":"Risks and benefits of direct oral anticoagulants across the spectrum of GFR among incident and prevalent patients with atrial fibrillation","volume":"13","author":"Shin","year":"2018","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2019.11.027_bib108","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1016\/j.amjmed.2019.06.006","article-title":"Efficacy and safety of oral anticoagulants in patients with atrial fibrillation and stages 4 or 5 chronic kidney disease","volume":"132","author":"Chang","year":"2019","journal-title":"Am J Med"},{"key":"10.1016\/j.kint.2019.11.027_bib109","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1093\/ndt\/gfz040","article-title":"Pros and cons of antithrombotic therapy in end-stage kidney disease: a 2019 update","volume":"34","author":"Burlacu","year":"2019","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kint.2019.11.027_bib110","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1016\/j.amjmed.2019.04.013","article-title":"Rivaroxaban versus warfarin in patients with nonvalvular atrial fibrillation and severe kidney disease or undergoing hemodialysis","volume":"132","author":"Coleman","year":"2019","journal-title":"Am J Med"},{"key":"10.1016\/j.kint.2019.11.027_bib111","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1161\/CIRCULATIONAHA.118.035418","article-title":"Outcomes associated with apixaban use in patients with end-stage kidney disease and atrial fibrillation in the United States","volume":"138","author":"Siontis","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.kint.2019.11.027_bib112","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1177\/1060028018781853","article-title":"Safety and efficacy of apixaban versus warfarin in patients with advanced chronic kidney disease","volume":"52","author":"Schafer","year":"2018","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.kint.2019.11.027_bib113","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1002\/rth2.12083","article-title":"Safety and effectiveness of apixaban compared to warfarin in dialysis patients","volume":"2","author":"Reed","year":"2018","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.kint.2019.11.027_bib114","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1159\/000491881","article-title":"The successful use of apixaban in dialysis patients with calciphylaxis who require anticoagulation: a retrospective analysis","volume":"48","author":"Garza-Mayers","year":"2018","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.kint.2019.11.027_bib115","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.thromres.2018.07.029","article-title":"Venous thromboembolism, factor VIII and chronic kidney disease","volume":"170","author":"Cheung","year":"2018","journal-title":"Thromb Res"},{"key":"10.1016\/j.kint.2019.11.027_bib116","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1097\/FTD.0000000000000356","article-title":"Effect of the direct oral anticoagulants rivaroxaban and apixaban on the disposition of calcineurin inhibitors in transplant recipients","volume":"39","author":"Vanhove","year":"2017","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.kint.2019.11.027_bib117","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1053\/j.ajkd.2009.04.024","article-title":"Acute kidney injury during warfarin therapy associated with obstructive tubular red blood cell casts: a report of 9 cases","volume":"54","author":"Brodsky","year":"2009","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.kint.2019.11.027_bib118","doi-asserted-by":"crossref","first-page":"935","DOI":"10.2215\/CJN.02470319","article-title":"Anticoagulant-related nephropathy: it\u2019s the real McCoy","volume":"14","author":"Glassock","year":"2019","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2019.11.027_bib119","doi-asserted-by":"crossref","first-page":"2787","DOI":"10.1681\/ASN.2018070741","article-title":"Anticoagulant-related nephropathy","volume":"29","author":"Brodsky","year":"2018","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2019.11.027_bib120","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1007\/s11239-018-1626-1","article-title":"Incidence and risk factors for acute kidney injury in patients with excessive anticoagulation on warfarin: a retrospective study","volume":"45","author":"Piran","year":"2018","journal-title":"J\u00a0Thromb Thrombolysis"},{"key":"10.1016\/j.kint.2019.11.027_bib121","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1093\/ckj\/sfy133","article-title":"Anticoagulant-related nephropathy: systematic review and meta-analysis","volume":"12","author":"de Aquino Moura","year":"2019","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.kint.2019.11.027_bib122","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/ki.2011.44","article-title":"Warfarin-related nephropathy occurs in patients with and without chronic kidney disease and is associated with an increased mortality rate","volume":"80","author":"Brodsky","year":"2011","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2019.11.027_bib123","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1002\/pds.3791","article-title":"Risk of renal failure with the non-vitamin K antagonist oral anticoagulants: systematic review and meta-analysis","volume":"24","author":"Caldeira","year":"2015","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"8","key":"10.1016\/j.kint.2019.11.027_bib124","article-title":"Efficacy and safety of apixaban, dabigatran, rivaroxaban, and warfarin in Asians with nonvalvular atrial fibrillation","volume":"7","author":"Chan","year":"2018","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1016\/j.kint.2019.11.027_bib125","doi-asserted-by":"crossref","first-page":"2621","DOI":"10.1016\/j.jacc.2017.09.1087","article-title":"Renal outcomes in anticoagulated patients with atrial fibrillation","volume":"70","author":"Yao","year":"2017","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.kint.2019.11.027_bib126","doi-asserted-by":"crossref","first-page":"2481","DOI":"10.1016\/j.jacc.2015.03.577","article-title":"Changes in renal function in patients with atrial fibrillation: an analysis from the RE-LY trial","volume":"65","author":"Bohm","year":"2015","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.kint.2019.11.027_bib127","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1161\/CIRCULATIONAHA.116.021890","article-title":"On-treatment outcomes in patients with worsening renal function with rivaroxaban compared with warfarin: insights from ROCKET AF","volume":"134","author":"Fordyce","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.kint.2019.11.027_bib128","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.amjmed.2015.11.032","article-title":"Warfarin and vascular calcification","volume":"129","author":"Poterucha","year":"2016","journal-title":"Am J Med"},{"key":"10.1016\/j.kint.2019.11.027_bib129","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.thromres.2017.07.020","article-title":"Assessing renal function in patients receiving DOACs: Cockcroft-Gault versus estimated glomerular filtration rate","volume":"157","author":"Kruger","year":"2017","journal-title":"Thromb Res"},{"key":"10.1016\/j.kint.2019.11.027_bib130","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1111\/jgs.14288","article-title":"Potential effect of substituting estimated glomerular filtration rate for estimated creatinine clearance for dosing of direct oral anticoagulants","volume":"64","author":"Schwartz","year":"2016","journal-title":"J\u00a0Am Geriatr Soc"},{"key":"10.1016\/j.kint.2019.11.027_bib131","first-page":"75","article-title":"Pharmacokinetics of warfarin in the nephrotic syndrome and effect on vitamin K-dependent clotting factors","volume":"25","author":"Ganeval","year":"1986","journal-title":"Clin Nephrol"},{"key":"10.1016\/j.kint.2019.11.027_bib132","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1007\/s13730-019-00381-9","article-title":"Direct oral anticoagulant successfully used to treat an adult nephrotic patient complicated with portal vein thrombosis","volume":"8","author":"Obata","year":"2019","journal-title":"CEN Case Rep"},{"key":"10.1016\/j.kint.2019.11.027_bib133","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1177\/1060028014549349","article-title":"Use of rivaroxaban in a patient with history of nephrotic syndrome and hypercoagulability","volume":"48","author":"Dupree","year":"2014","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.kint.2019.11.027_bib134","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1159\/000362162","article-title":"Carotid thromboembolism associated with nephrotic syndrome treated with dabigatran","volume":"4","author":"Sasaki","year":"2014","journal-title":"Case Rep Nephrol Urol"},{"key":"10.1016\/j.kint.2019.11.027_bib135","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1001\/archinte.165.10.1095","article-title":"Systematic overview of warfarin and its drug and food interactions","volume":"165","author":"Holbrook","year":"2005","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.kint.2019.11.027_bib136","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.phrs.2018.07.016","article-title":"Pharmacokinetic drug interactions of the non-vitamin K antagonist oral anticoagulants (NOACs)","volume":"135","author":"Gelosa","year":"2018","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.kint.2019.11.027_bib137","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1002\/psp4.12382","article-title":"Assessing potential drug-drug interactions between dabigatran etexilate and a P-glycoprotein inhibitor in renal impairment populations using physiologically based pharmacokinetic modeling","volume":"8","author":"Doki","year":"2019","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"10.1016\/j.kint.2019.11.027_bib138","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1001\/jama.2017.13883","article-title":"Association between use of non-vitamin K oral anticoagulants with and without concurrent medications and risk of major bleeding in nonvalvular atrial fibrillation","volume":"318","author":"Chang","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.kint.2019.11.027_bib139","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1182\/blood-2015-06-651539","article-title":"Improving evidence on anticoagulant therapies for venous thromboembolism in children: key challenges and opportunities","volume":"126","author":"Goldenberg","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.kint.2019.11.027_bib140","doi-asserted-by":"crossref","first-page":"e500","DOI":"10.1016\/S2352-3026(19)30161-9","article-title":"Bodyweight-adjusted rivaroxaban for children with venous thromboembolism (EINSTEIN-Jr): results from three multicentre, single-arm, phase 2 studies","volume":"6","author":"Monagle","year":"2019","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.kint.2019.11.027_bib141","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1111\/jth.13847","article-title":"Phase IIa study of dabigatran\u00a0etexilate in children with venous thrombosis: pharmacokinetics, safety, and tolerability","volume":"15","author":"Halton","year":"2017","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.kint.2019.11.027_bib142","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1007\/s40262-013-0094-1","article-title":"Pharmacokinetics and pharmacodynamics of anticoagulants in paediatric patients","volume":"52","author":"Yee","year":"2013","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.kint.2019.11.027_bib143","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1055\/s-0038-1668132","article-title":"Anticoagulant effects of dabigatran in paediatric patients compared with adults: combined data from three paediatric clinical trials","volume":"118","author":"Maas","year":"2018","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.kint.2019.11.027_bib144","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1097\/MBC.0000000000000033","article-title":"The in-vitro anticoagulant effect of rivaroxaban in neonates","volume":"25","author":"Attard","year":"2014","journal-title":"Blood Coagul Fibrinolysis"},{"key":"10.1016\/j.kint.2019.11.027_bib145","doi-asserted-by":"crossref","first-page":"85","DOI":"10.5482\/HAMO-13-06-0033","article-title":"Phamacokinetics of rivaroxaban in adolescents","volume":"34","author":"Beyer-Westendorf","year":"2014","journal-title":"Hamostaseologie"}],"container-title":["Kidney International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253819312487?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253819312487?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T00:55:55Z","timestamp":1758761755000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0085253819312487"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4]]},"references-count":145,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["S0085253819312487"],"URL":"https:\/\/doi.org\/10.1016\/j.kint.2019.11.027","relation":{},"ISSN":["0085-2538"],"issn-type":[{"value":"0085-2538","type":"print"}],"subject":[],"published":{"date-parts":[[2020,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Role of direct oral anticoagulants in patients with\u00a0kidney disease","name":"articletitle","label":"Article Title"},{"value":"Kidney International","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.kint.2019.11.027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 International Society of Nephrology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}